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Selected polyphenols potentiate the 
apoptotic efficacy of glycolytic inhibitors 
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Abstract 
Background: The glycolysis inhibitor 2‑deoxy‑d‑glucose (2‑DG) is a safe, potentially useful anti‑tumour drug, but its 
efficacy is normally low when used alone. Recent studies indicated that 2‑DG stimulates the PI3K/Akt and MEK/ERK 
defensive pathways, which limits the apoptotic efficacy in tumour cell lines. We hypothesized that co‑treatment with 
selected polyphenols could improve 2‑DG‑provoked apoptosis by preventing defensive kinase activation.
Methods: Cell proliferation was measured by cell counting or the MTT assay. Cell cycle, apoptosis and necrosis were 
determined by propidium iodide staining and/or annexin V labeling followed by flow cytometry. Mitochondria pore 
transition and depolarization were determined by calcein‑ATM or rhodamine 123 labeling followed flow cytometry. 
Intracellular reactive oxygen species and GSH were determined by dichlorodihydrofluorescein diacetate or mono‑
chlorobimane labeling followed by flow cytometry or fluorimetry. Expression and phosphorylation of protein kinases 
were analyzed by the Western blot.
Results: (i) 2‑DG‑provoked apoptosis was greatly potentiated by co‑treatment with the sub‑lethal concentrations of 
the flavonoid quercetin in human HL60 acute myeloblastic leukemia cells. Allowing for quantitative differences, apop‑
tosis potentiation was also obtained using NB4 promyelocytic and THP‑1 promonocytic cells, using curcumin or gen‑
istein instead of quercetin, and using lonidamine instead of 2‑DG, but not when 2‑DG was substituted by incubation 
in glucose‑free medium. (ii) Quercetin and 2‑DG rapidly elicited the opening of mitochondria pore transition, which 
preceded the trigger of apoptosis. (iii) Treatments did not affect GSH levels, and caused disparate effects on reac‑
tive oxygen species generation, which did not match the changes in lethality. (iv) 2‑DG and lonidamine stimulated 
defensive Akt and ERK phosphorylation/activation, while glucose starvation was ineffective. Polyphenols prevented 
the stimulation of Akt phosphorylation, and in some cases also ERK phosphorylation. In addition, quercetin and 2‑DG 
stimulated GSK‑3α,β phosphorylation/inactivation, although with different isoform specificity. The use of pharmaco‑
logic inhibitors confirmed the importance of these kinase modifications for apoptosis.
Conclusions: The present in vitro observations suggest that co‑treatment with low concentrations of selected poly‑
phenols might represent a manner of improving the poor anti‑tumour efficacy of some glycolytic inhibitors, and that 
apoptosis potentiation may be at least in part explained by the regulation of defensive protein kinase activities.
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publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
A characteristic of tumour cells is the profound re-
organization of metabolic parameters in relation to 
their healthy counterparts, allowing them to obtain the 
macromolecular constituents required for their rapid 
de-regulated growth and also as alternative sources of 
energy [1–3]. One of the best known modifications is the 
increased dependence on glucose metabolism instead of 
oxidative phosphorylation, even under aerobic conditions 
(a property known as “aerobic glycolysis” or “Warburg’’ 
effect). This peculiarity made possible the development 
of glycolysis-targeting drugs as potential anti-cancer 
agents. This category includes, among others, the glu-
cose inactive analog 2-deoxy-d-glucose (2-DG) [4], the 
indazole derivative lonidamine (Lon) [5], and the small 
alkylating drug 3-bromopyruvate (3-BrP) [6]. Allowing 
for the disparity in chemical structure and hence in bio-
chemical and molecular effects, these drugs target criti-
cal enzymes in the glycolytic pathway, namely hexokinase 
II (HKII) in the case of 2-DG and Lon [5, 7], and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) and to a 
lower extent HKII in the case of 3-BrP [8]. While promis-
sory results have been obtained in clinical assays [5, 6, 9, 
10], the efficacy of these agents is different. Thus, 3-BrP 
is quite toxic per se, while 2-DG and Lon are well toler-
ated but poorly efficacious in monotherapy. Nonetheless, 
2-DG and Lon may be useful as radio- and chemo-sen-
sitizing agents, overcoming resistance and increasing 
cyto-reduction by conventional anti-tumour treatments 
[4, 5, 9]. Using combinatory assays with the anti-leukemic 
agent arsenic trioxide (Trisenox), we recently demon-
strated that a common effect of the anti-glycolytic drugs 
is the stimulation (albeit with different kinetics and inten-
sity) of Akt/mTOR and MEK/ERK defensive pathways in 
several human acute myeloid leukemia (AML) cell lines, 
and that this stimulation restrains the apoptotic efficacy 
of 2-DG and Lon when used as single agents [11, 12]. 
Akt and/or ERK activation by 2-DG was also observed in 
other tumour cell models [13–15].
Polyphenols represent a large collection of molecules 
present in the plant kingdom. At the low doses attainable 
in the daily diet these compounds exert multiple protec-
tive functions (e.g., against cellular oxidation, inflam-
mation, aging, tumour initiation…). On the other hand, 
at high albeit still pharmacologically attainable concen-
trations many polyphenols selectively induce apopto-
sis in tumour cells, and exhibit clinical efficacy either 
alone or in combination with conventional anti-cancer 
drugs [16]. While the multiplicity of biochemical actions 
makes impossible to unequivocally ascribe their anti-
cancer action to a single mechanism, a frequent effect of 
polyphenols is the inhibition of the PI3K/Akt defensive 
pathway [17, 18]. For instance, the flavonoid quercetin 
(Quer) is the natural analog of 2-(4-Morpholinyl)-8-phe-
nyl-4H-1-benzopyran-4-one (LY294002), a potent PI3K 
inhibitor commonly used in laboratory research [19]. We 
previously observed that prolonged treatment (24–48 h) 
with sub-lethal concentrations of Quer, curcumin (Cur) 
and genistein (Gen) reduced the constitutive Akt phos-
phorylation in U937 and HL60 AML cells [20–22]. On 
this ground, we hypothesized the pre-treatment with 
polyphenols might prevent Akt activation and as a con-
sequence improve the lethality of glycolytic inhibitors. 
With this hypothesis in mind, in the present work we 
analyze the capacity of Quer, Cur and Gen to cooper-
ate with 2-DG and Lon to induce apoptosis in HL60 and 
other AML cell lines. The regulatory function of Akt and 
other protein kinases, as well as the potential importance 
of other factors such as mitochondrial dysfunction and 
oxidative stress, are examined.
Methods
Reagents and antibodies
All components for cell culture were obtained from 
Invitrogen, Inc. (Carlsbad, CA). Dichlorodihydro-
fluorescein diacetate (H2DCFDA) and monochloro-
bimane were obtained from Molecular Probes, Inc. 
(Eugene, OR). The kinase inhibitors 1,4-Diamino-
2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene 




hydrate (triciribine hydrate, Akt inhibitor V), 
4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-
pyridyl)-1H-imidazole (SB203580), and the caspase 
inhibitor Z-Val-Ala-Asp(OMe)-CH2F (z-VAD-fmk), 
were obtained from Calbiochem (Darmstad, Germany), 
and 1-5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-
morpholin-4-yl-ethoxy)naphthalene-1-yl] urea (BIRB 
796) from Shelleck (Houston, TX). Rabbit anti-human 
p44/42 MAP kinase, phospho-p44/p42 MAP kinase 
(Thr202/Tyr204), Akt, phospho-Akt (Ser473) (D9E) 
XP™, p38 MAP kinase, phospho-p38 MAP kinase 
(Thr180/Tyr182), phospho-GSK-3α/β (Ser21/9), and 
phospho-S6 ribosomal protein (Ser235/236) polyclonal 
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antibodies, were obtained from Cell Signaling Technol-
ogy Inc. (Danvers, MA). Mouse GSK-3α/β monoclonal 
antibody (0011-A) was obtained from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA). Peroxidase-conju-
gated immunoglobulin G antibodies were from DAKO 
Diagnostics, S.A. (Barcelona, Spain). All other non-
mentioned reagents and antibodies were from Sigma 
(Madrid, Spain).
Cells and treatments
HL60 myeloblastic cells [23] and THP-1 promononocytic 
cells [24] were obtained from our institutional repository 
(CIB), and NB4 promyelocytic cells [25] were kindly sup-
plied by Profs. M.D. Delgado and J. León (Departamento 
de Biología Molecular, Facultad de Medicina, Univer-
sidad de Cantabria, Santander, Spain). These cell lines 
represent distinct subtypes of human AML cells (HL60, 
M2; NB4, M3; THP-1, M5, according to the classifica-
tion of the French-American-British (FAB) cooperative 
group), with substantial differences in molecular and 
biochemical parameters, and hence in the capacity of 
response to anti-cancer agents. Absence of mycoplasma 
contamination, and authentication by STR analysis, spe-
cific antigen expression, and PML-RARα fusion protein 
expression (NB4 cells) were corroborated by us or our 
technical staff. Cell handling (and all experimental pro-
cedures in general) was carried out strictly following the 
regulations of the Bioethics and Biosafety Commission 
of our Institution (Centro de Investigaciones Biológicas, 
CSIC). Conditions of cell growth and treatment were 
described in detail in preceding publications [11, 12]. For 
glucose starvation (Glu−), cells were extensively washed 
with phosphate-buffered saline (PBS) and then seeded at 
the appropriate concentration in glucose-lacking RPMI 
medium supplemented with 10 % (v/v) serum. For good 
comparison, the corresponding controls were subject to 
the same manipulation, but finally seeded in complete 
medium (Glu+).
Calcein-AM was commercially obtained as a 4  mM 
solution in dimethyl sulfoxide. Rhodamine 123 (R123, 
1 mg/ml) was prepared in ethanol. Stock solutions of Lon 
(100 mM), Quer (100 mM), Gen (50 mM), Cur (20 mM), 
H2DCFDA (5  mM), monochlorobimane (200  mM), 
U0126 (2.63  mM), PD98059, LY294002 and triciribine 
(20 mM each), SB203580 (13,2 mM), SB216763 (50 mM), 
BIRB 796 (0.1 mM) and z-VAD-fmk (25 mM) were pre-
pared in dimethyl sulfoxide. 3(4,5-Dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) was 
dissolved at 5  mg/ml in PBS. All these solutions were 
stored at −20  °C. A stock solution of propidium iodide 
(PI, 1 mg/ml) was prepared in phosphate buffered saline 
(PBS), and stored at 4  °C. 2-DG and DL-buthionine-
(S,R)-sulfoximine (BSO) were freshly prepared at 250 
and 50  mM, respectively, in PBS. 3-Bromopyruvate was 
freshly prepared at 30  mM in PBS, and the pH of the 
solution was adjusted at 7.2 with NaOH.
Flow cytometry
The analysis of samples was carried out on an EPICS 
XL flow cytometer (Coulter, Hialeah, FL) equipped with 
an air-cooled argon laser tuned to 488 nm. The specific 
fluorescence signal corresponding to fluorescein isothio-
cyanate, H2DCFDA, calcein-AM and R123 was collected 
with a 525-nm band pass filter, and the signal corre-
sponding to PI with a 620-nm band pass filter. A total of 
104 cells were scored in each determination.
Cell proliferation, cell cycle, apoptosis and necrosis
Total cell proliferation was measured by cell counting 
of trypan-blue excluding cells, or by means of the MTT 
colorimetric assay. This later procedure gives an indi-
rect estimation of the relative number of viable cells in 
the culture, based on changes in mitochondrial meta-
bolic activity. Cell cycle phase distribution was routinely 
determined by cell permeabilization followed by PI stain-
ing and flow cytometry analysis. When convenient, the 
resulting histograms were analyzed with the FlowLogic 
program (Inivai, Victoria, Canada). This technique also 
provided an estimation of the frequency of apoptotic 
cells, characterized by low (sub-G1) DNA content. The 
criterion used for necrosis was the loss of plasma mem-
brane integrity, as determined by free PI uptake into 
non-permeabilized cells and flow cytometry analysis. In 
addition, apoptosis and necrosis were determined simul-
taneously by double labeling with annexin V-FITC and 
PI followed by flow cytometry measurement using an 
Annexin V-FITC Apoptosis Detection Kit (Immunostep, 
Salamanca, Spain). This procedure allows the distinction 
between viable cells (annexin V-negative/PI-negative), 
early apoptotic cells (annexin V-positive/PI-negative), 
late apoptotic or necrotic cells (annexin V-positive/PI-
positive), and genuine necrotic cells (annexin-V negative/
PI-positive). Since the loss of plasma membrane integrity 
leading to free PI penetration is compatible with both 
genuine necrosis and late apoptosis (also termed “sec-
ondary” necrosis), the pan-caspase inhibitor z-VAD-fmk 
was occasionally used to discriminate between these 
two possibilities. A detailed description of all these tech-
niques can be found in our preceding works [21, 26, and 
references therein].
Mitochondrial membrane permeabilization and membrane 
potential dissipation
Inner mitochondrial membrane permeabilization 
(mIMP) was determined using the calcein-AM/CoCl2 
method, originally reported by Petronilli et al. [27]. Our 
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adaptation for flow cytometry using HL60 cells was 
already described in a preceding article [11]. Mitochon-
drial membrane potential (ΔΨm) was determined using 
the cationic agent R123 and flow cytometry analysis, as 
previously described [26].
Reactive oxygen species and reduced glutathione levels
The intracellular accumulation of reactive oxygen spe-
cies (ROS) was measured by flow cytometry using the 
ROS-sensitive probe H2DCFDA. The intracellular level of 
reduced glutathione (GSH) was measured in a Varioskan 
Flash microplate reader (Thermo Fisher Scientific Inc, 
Waltham, MA) at excitation wavelength of 390  nm and 
emission wavelength of 520  nm, using the fluorescent 
probe monochlorobimane. The detailed procedures were 
described in a previous publication [26].
Immunoblotting
Cells were collected by centrifugation, washed with PBS 
and total protein extracts were obtained by lysing them 
for 20 min at 4 °C in a buffer consisting of 20 mM Tris–
HCl (pH 7.5) containing 137  mM NaCl, 2  mM EDTA, 
10  % (v/v) glycerol, and 1  % Nonidet P-40, and supple-
mented with a protease inhibitor cocktail, 1 mM sodium 
orthovanadate, and 10  mM NaF. After brief sonication 
and centrifugation for 15  min at 10,000×g at 4  °C, the 
supernatants were collected, and samples containing 
equal amounts of proteins were resolved by SDS–poly-
acrylamide gel electrophoresis. The proteins were then 
transferred to polyvinylidene fluoride (PVDF) mem-
branes and immunodetected, as previously described 
[28]. When convenient, the relative band intensities were 
quantified using the Quantity One 1-D Analysis Soft-
ware, version 4.6 (Bio-Rad Laboratories, Inc., Hercules, 
CA).
Data analysis and presentation
Except when indicated, all experiments were repeated at 
least three times, and as a rule the results are expressed 
as the mean value  ±  SD. Statistical analyses were car-
ried out using one way ANOVA with Dunnett or Bonfer-
roni post-test, using SAS version 9.4 (SAS Institute, Cary 
NC). The Dunnett’s method was followed when compar-
ing different treatments with controls, and Bonferroni’s 
when pairwise comparisons were performed. The sym-
bols used were: &, to compare treatment vs. control; *, to 
compare pairs of single treatments; and #, to indicate that 
the value in a combined treatment is higher than the sum 
of values in the corresponding single treatments. Sum of 
values were obtained by considering single treatment as 
independent random variables. In all cases, single symbol 
means p < 0.05, double symbol p < 0.01, and triple sym-
bol p < 0.001. n.s., non-significant.
Results
Cell proliferation and cell death
Firstly, we examined the capacity of Quer and 2-DG, 
alone and in combination, to affect proliferation activity 
and induce apoptosis at 24 h of treatment in HL60 cells. 
Because of the hypothesis advanced in the ‘‘Background’’ 
section, namely that polyphenols might prevent early 
regulatory gene responses elicited by metabolic inhibi-
tors, in the combined treatments Quer was applied 2  h 
before 2-DG (and except when otherwise indicated, this 
procedure will be also followed in all experiments along 
the whole work). As shown in Fig.  1a, treatment with 
5–20  μM Quer or 1–5  mM 2-DG separately caused a 
concentration-dependent decrease in viable cell number, 
as determined by the MTT assay, and the response was 
augmented when the drugs were used in combination. 
In spite of the evident effect on proliferation, treatment 
with either 5–20  µM Quer or 1-5  mM 2-DG separately 
caused very low (less than 10  %) apoptotic effect, as 
measured by the frequency of cells with sub-G1 DNA 
content in flow cytometry assays. Nonetheless, apopto-
sis was greatly potentiated in more than additive manner 
when the drugs were used in combination (Fig. 1b, c). On 
the ground of the obtained results, the concentrations 
(See figure on next page.) 
Fig. 1 Effect of quercetin and 2‑deoxy‑d‑glucose on cell viability and apoptosis generation. HL60 cells were either kept untreated (Cont) or treated 
with quercetin (Quer) and 2‑deoxy‑d‑glucose (2‑DG), alone and in combination. In the combined treatments the cells were pre‑treated with Quer 
for 2 h, followed by addition of 2‑DG for 24 h more, and with the occasional presence of the pan‑caspase inhibitor z‑VAD‑fmk (50 μM). Drug con‑
centrations are indicated as subheadings (Quer, μM; 2‑DG, mM). When nothing is indicated, Quer was used at 20 μM and 2‑DG at 5 mM. a Changes 
in cell viability, as evidenced by the MTT assay. Absorption values are expressed in relation to the control. b Frequency of apoptosis, represented 
by the sub‑population of cells with sub‑G1 DNA content obtained by flow cytometry. Examples of histograms showing cell cycle phases (G1, S and 
G2/M) and sub‑G1 (Ap) are presented in c. d Frequency of early and late apoptotic cells, measured by cell surface annexin V binding and propidium 
iodide (PI) exclusion or uptake, respectively. e Flow cytometry histograms showing the frequency of PI‑permeable cells, indicating plasma mem‑
brane disruption. The bar charts in (a–b) represent the mean ± S.D. of at least three determinations, measured by duplicate. The histograms in (d, 
e) are representative of one out of three determinations with similar results. Symbols mean: (*) significant differences between single treatments; (#) 
significant differences between the combined treatment and the sum of values in the corresponding individual treatments (e.g., co‑incubation with 
20 μM Quer and 5 mM 2‑DG, in relation to the sum of 20 μM Quer alone plus 5 mM 2‑DG alone) (n.s. non‑significant). To better discern differences, 
in this case the sum of values in individual treatments is indicated by a thick black bar within the bar corresponding to the combined treatment. 
Single symbol, p < 0.05; double symbol, p < 0.01; triple symbol, p < 0.001
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of 20  µM Quer and 5  mM 2-DG were selected for the 
following experiments, except when otherwise indi-
cated. The cooperative apoptotic action between Quer 
and 2-DG was confirmed using the annexin V/PI assay 
(Fig.  1d). Moreover, the pan-caspase inhibitor z-VAD-
fmk almost totally abrogated the formation of apoptotic 
cells (Fig. 1b–d), corroborating that cell death represents 
genuine caspase-dependent apoptosis. Of note, treat-
ment with Quer plus 2-DG resulted in free PI uptake by a 
high proportion of cells. Nevertheless, this effect was also 
suppressed by z-VAD-fmk (Fig. 1e), indicating that these 
cells represent late apoptosis (or “secondary necrosis”) 
instead of a genuine necrotic response. Finally, a time-
course study (3–24 h) revealed that significant more than 
additive drug cooperation was firstly detectable at 6 h of 
treatment (approx. 15 % apoptosis in the combined treat-
ment), and increased thereafter (see Additional file 1: Fig. 
S1). Thus, except when otherwise indicated, 6 h was the 
maximum time period used for further investigation of 
early regulatory events.
In a new set of experiments, 2-DG was combined 
with Cur (8 μM) and Gen (50 μM) instead of Quer. The 
suitability of these concentrations for combinatory stud-
ies in leukemia cell models was established in earlier 
publications [21, 29]. Some of the obtained results are 
presented in Fig. 2a, b. Cur alone caused negligible apop-
tosis but cooperated with 2-DG with similar efficacy as 
Quer (Fig. 2a). On the other hand, the efficacy of coop-
eration using 50 μM Gen was very low, and the concen-
tration had to be increased to 100  μM (which is per se 
moderately lethal) to obtain a more satisfactory response 
(Fig.  2b). The results with both Cur and Gen were cor-
roborated using annexin V/PI analysis (see Additional 
file 2: Fig. S2).
In addition, we examined the possible cooperation 
between Quer and 2-DG in NB4 promyelocytic and 
THP-1 promonocytic cells. Among other biochemi-
cal aspects, these cells exhibit marked differences in the 
metabolic phenotype: NB4 cells are highly dependent 
on glycolysis, while THP-1 cells may compensate glyco-
lysis inhibition with fatty acid β-oxidation [30]. Accord-
ingly, Fig. 2c, d shows that NB4 cells are more susceptible 
and THP-1 cells less susceptible to the cytotoxic action 
of 2-DG than HL60 cells. The figure also indicates more 
Fig. 2 Apoptosis generation by other polyphenols, and by 2‑deoxy‑d‑glucose and quercetin in other cell lines. (a, b) HL60 cells were incubated 
with the indicated concentrations of (a) curcumin (Cur, μM) or (b) genistein (Gen, μM) and 2‑DG (mM), alone or in combination. c NB4 cells and d 
THP‑1 cells were incubated with the indicated concentrations of Quer (μM) and 2‑DG (mM), alone and in combination. The frequency of apoptosis 
(cells with sub‑G1 DNA content) was estimated by flow cytometry. Other conditions, including pre‑incubation with polyphenols in the combined 
treatments and symbols used in statistical analysis, were as in Fig. 1
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than additive cooperation between Quer and 2-DG in 
both cell lines, although with lower efficacy than in HL60 
cells. Of note, the lower apoptotic efficacy was not due 
to a switch to a genuine necrotic response, since free 
PI uptake was almost totally suppressed by the caspase 
inhibitor (23.3 ±  1.1 vs. 5.8 ±  0.7 % positive cells upon 
treatment with 10  μM Quer plus 2.5  mM 2-DG in the 
absence and presence of z-VAD-fmk, respectively, in NB4 
cells; and 19.3 ± 1.2 vs. 4.7 ± 1.0 % upon treatment with 
20  μM Quer plus 20  mM 2-DG in the absence and the 
presence of z-VAD-fmk, respectively, in THP-1 cells).
It has been reported that flavonoids such as Quer and 
Gen may inhibit glucose and 2-DG uptake in different 
cell models, including AML cells, probably by affecting 
glucose transporter (GLUT-1) [31, 32]. For this reason 
new experiments were carried out using Lon, a HKII 
inhibitor structurally unrelated to 2-DG. The concentra-
tions of 50 and 100  μM Lon were adopted as adequate 
for combinatory studies, according to our previous pub-
lications [11, 21]. The lethality of Lon alone was very 
low, but efficaciously cooperated with Quer, Cur and 
Gen to induce apoptosis in HL60 cells, as demonstrated 
by the frequency of cells with sub-G1 DNA content 
(Fig. 3a–c), and confirmed in the case of Quer plus Lon 
by the annexin V/PI assay (see Additional file 2: Fig. S2). 
The protective action of z-VAD-fmk corroborated again 
that cell death represented caspase dependent apoptosis 
(Fig. 3a, c), and that the concomitant free PI uptake was 
attributable to late apoptosis instead of genuine necrosis 
(38 ± 1.7 % vs 7.2 ± 0.7 PI-permeable cells upon treat-
ment with 20 μM Quer plus 100 μM Lon in the absence 
and the presence of z-VAD-fmk, respectively).
Finally, we performed a set of experiments in which, 
instead of being treated with 2-DG, HL60 cells were 
cultured for 24  h in glucose–lacking (Glu−) medium, 
either in the absence or the presence of Quer. Both 2-DG 
treatment in complete (Glu+) medium and cell incu-
bation in Glu− medium resulted in partial depletion 
(approximately 40  % at 16  h) of intracellular ATP levels 
[12], and in cell proliferation inhibition (measured by cell 
counting), which in the case of Glu− was exacerbated 
by addition of Quer (Fig.  3d). However, cells cultured 
in Glu− were viable, and the generation of apoptosis by 
Quer/Glu− was very low, in comparison to Quer plus 
Fig. 3 Effect lonidamine, glucose deprivation, and polyphenols on proliferation and apoptosis. (a–c) Frequency of apoptosis upon incubation of 
HL60 cells with the indicated concentrations (μM) of a Quer, b Cur, c Gen, and lonidamine (Lon), alone and in combination. (d–f) The bar charts 
indicate (d) the relative cell number, as an estimation of proliferation rate, (e) apoptosis, and (f) free PI uptake upon 24 h culture of HL60 cells in 
medium lacking glucose (Glu−), with or without Quer. Values in (d) are expressed in relation to cultures maintained in complete (glucose‑contain‑
ing) medium. In all cases, treatments with 2‑DG alone or with Quer plus 2‑DG are included as controls. Symbol (&) mean significant differences in 
relation to Cont. Other conditions, including pre‑incubation with polyphenols in the combined treatments and other symbols used in statistical 
analysis, were as in Fig. 1
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2-DG in complete medium (Fig. 3e). Again, the low apop-
totic rate was not compensated by a switch to a necrotic 
response, as indicated by the low frequency of cells with 
free PI uptake (Fig. 3f ).
Mitochondrial dysfunction
2-DG causes mitochondrial HKII inhibition and detach-
ment and may therefore induce mIMP [7], as we pre-
viously corroborated in HL60 cells [12]. In addition, 
it has been reported that Quer may induce mIMP in 
isolated mitochondria by direct interaction with the 
adenine nucleotide translocase [33], although another 
study indicated both mIMP induction or inhibition, 
depending on the assay conditions [34]. In the present 
work, mitochondria dysfunction was firstly analyzed by 
measuring changes in ΔΨm after 14  h treatment with 
20  μM Quer and 5  mM 2-DG, alone and in combina-
tion. The results are represented in Fig. 4a. Allowing for 
a slight ΔΨm increase by Quer alone, the most promi-
nent effect was the appearance of a large subpopulation 
of cells with markedly low ΔΨm in the combined treat-
ment. This subpopulation was suppressed by z-VAD-
fmk, and hence likely represents the fraction of cells 
undergoing apoptosis. Then, a second set of experiments 
was carried out using the calcein/CoCl2 procedure, 
which is considered to provide a direct and more accu-
rate determination of mIMP [35]. The results in Fig.  4b 
indicate that 2-DG (5  mM) and Quer (10–40  μM, in a 
Fig. 4 Mitochondrial transmembrane potential (ΔΨm) dissipation and inner mitochondrial membrane permeabilization (mIMP). HL60 cells were 
treated with Quer and 2‑DG, alone or in combination. When indicated, the cells were also co‑incubated with the pan‑caspase inhibitor z‑VAD‑fmk 
(50 μM). a Flow cytometry histograms representing ΔΨm alterations at 14 h treatment with 20 μM Quer and 5 mM 2‑DG, as indicated by changes 
in R123‑derived fluorescence. Note the appearance of a discrete sub‑population with low ΔΨm in the combined treatment, which disappears by 
application of z‑VAD‑fmk. b mIMP was measured by flow cytometry assays using the Calcein/CoCl2 procedure. The bar chart (bottom) indicates 
alterations at 4 h treatment, expressed in relation to untreated (Cont) cells. Some cytometry histograms using 20 μM Quer and 5 mM 2‑DG are 
represented as examples (top). In all cytometry histograms, the numbers into parenthesis indicate the corresponding mean value, and the vertical 
dotted lines represent the mean value in the Cont to better discern the displacements caused by the treatments. Other conditions, including pre‑
incubation with Quer in the combined treatments and symbols used in statistical analysis, were as in Figs. 1 and 3
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concentration-dependent manner) caused mIMP induc-
tion, as evidenced by the decrease in calcein-derived flu-
orescence, and the decrease was augmented when both 
drugs were used in combination. Of note, this response 
was detected at 4 h of treatment, preceding the first man-
ifestations of apoptosis execution (see Additional file  1: 
Fig. S1).
Oxidative stress
Although dietary polyphenols are normally considered as 
anti-oxidant, protective agents, there is ample evidence 
indicating that they may exert both anti-oxidant and pro-
oxidant effects, depending on the chemical structure and 
treatment conditions. For instance, it was reported that 
Quer may either decrease [36] or increase [37, 38] ROS 
production in HL60 cells, and ROS increase mediated 
apoptosis induction [38]. For these reasons, we evaluated 
possible alterations in intracellular ROS accumulation 
after short treatments (3 h) with Quer and 2-DG, alone 
and in combination, using the ROS-sensitive fluorescent 
probe H2DCFDA. Some of the obtained results are pre-
sented in Fig. 5a. It was observed that 2-DG (5 mM) and 
Fig. 5 Effect of polyphenols and glycolytic inhibitors on intracellular ROS and GSH levels. a Intracellular accumulation of ROS in HL60 cells, as 
determined by flow cytometry using H2DCFDA, upon treatment with the indicated concentrations of Quer, Cur, Gen and Lon (μM) or 2‑DG (mM), 
alone and in combination. The results in the bar chart are expressed in relation to untreated (Cont) cells. Cytometry histograms corresponding to 
untreated cells and cells incubated for 3 h with Quer plus 2‑DG are presented as examples. b Intracellular GSH levels in HL60 cells, as determined 
at 6 h of treatment by monochlorobimane derivatization in luminometric assays. 3‑BrP (60 μM) was used as a positive control (see Ref. [44]). The 
results are expressed in relation to untreated (Cont) cells (approximate GSH content, 8.5 nmol/106 cells). c Frequency of apoptosis inHL60 cells upon 
incubation for 24 h with 1 mM BSO, alone and in combination with 2‑DG or Lon. The combinations Quer plus 2‑DG and Quer plus Lon are included 
as positive controls. Symbols in (a, b) indicate significant differences in relation to Cont, and in (c) between the indicated pairs of values (n.s. non 
significant). Other conditions, including pre‑incubation with Quer in the combined treatments (a, b) and symbols used in statistical analysis, were as 
in Figs. 1 and 3
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Quer (10–40  μM, in a concentration-dependent man-
ner) reduced the basal intracellular ROS content in HL60 
cells, and the reduction was higher in the combined 
treatment. By contrast to Quer, Gen (50  μM) increased 
ROS levels (as previously reported [29]), but the increase 
was attenuated by combination with 2-DG. In a simi-
lar manner, and by contrast to 2-DG, Lon (100  μM) 
increased ROS content (as previously reported [11]), but 
this increase was totally abrogated by combination with 
Quer, reaching similar levels as with Quer alone. In sum-
mary, these results evidence large discrepancies in ROS 
production depending on the used treatment, which do 
not match and hence may not explain apoptosis potentia-
tion in the combined treatments (see Figs. 1–3).
We previously reported that prolonged Quer treat-
ment (14–24  h) reduced the intracellular GSH content 
in myeloid cells [20], while Gen and Cur were ineffective 
[21, 29]. In the present experiments we analyzed pos-
sible changes in GSH content upon short treatments of 
HL60 cells with Quer and the glycolytic inhibitors, using 
the GSH-sensitive fluorescent probe monochlorobimane. 
It was observed that GSH levels were not significantly 
affected by treatment for 3  h (data not shown) or 6  h 
(Fig. 5B) with 10–40 μM Quer, either alone or in combi-
nation with 2-DG (5 mM) or Lon (100 μM). Nonetheless, 
while these results exclude GSH as an early regulatory 
factor, we might not a priori exclude that a possible late 
depletion could have some effect on apoptosis progres-
sion. This possibility was indirectly investigated using 
BSO, a GSH specific synthesis inhibitor [39]. Treatment 
of HL60 cells with 1 mM BSO for 16 h caused a partial 
(35.3 ± 3.2 %) decrease in the basal GSH content, but the 
GSH inhibitor did not affect the proliferation rate (data 
not shown), nor caused cell lethality per se or in combi-
nation with 2-DG or Lon (Fig. 5c).
Protein kinase activation
As commented above (see ‘‘Background’’ section), we 
hypothesized that polyphenols might potentiate the 
apoptotic efficacy of glycolytic inhibitors by prevent-
ing the activation of defensive kinase pathways, either 
PI3K/Akt and/or MEK/ERK. To examine this hypoth-
esis, in a first set of experiments we examined Akt and 
ERK phosphorylation/activation upon 1 and 6  h treat-
ment of HL60 cells with Quer and 2-DG, alone and in 
combination (where, as previously indicated, Quer was 
applied 2 h before 2-DG). We also checked the response 
of S6-ribosomal protein (rpS6), which is downstream 
Akt; of GSK3α/β, which are phosphorylated by Akt and 
ERK [40, 41]; and of p38-MAPK, also described as a tar-
get of quercetin or quercetin-derived analogs in leuke-
mia cells [42, 43]. The results, presented in Fig.  6, were 
as follows: (i) 2-DG (5  mM) stimulated Akt and rpS6 
phosphorylation/activation, and the stimulation was 
abrogated or greatly attenuated by Quer. (ii) By contrast, 
ERK phosphorylation/activation was stimulated by both 
Quer and 2-DG, alone and in combination. (iii) Quer and 
2-DG, alone and in combination, stimulated GSK3α/β 
phosphorylation (Ser21/9)/inactivation. Quer alone 
exerted higher effect on the α isoform, while 2-DG alone 
stimulated both isoforms. (iv) Quer, alone or with 2-DG, 
Fig. 6 Effect of 2‑deoxy‑d‑glucose and quercetin on protein kinase 
activities. The figure shows the relative levels of phosphorylated (P) 
and total (T) Akt, ERKs, S6 ribosomal protein (rpS6), GSK‑3α,β, and 
p38‑MAPK, and β‑actin (assessed as a control of sample loading). 
HL60 cells were kept untreated, incubated for 1 or 6 h with 5 mM 
2‑DG alone, or incubated for 2 h with 20 μM Quer and then for 1 
or 6 h more with or without addition of 2‑DG. Whenever possible, 
band intensities of phosphorylated forms were measured, normal‑
ized with to the corresponding total form, and expressed in relation 
the Cont (arbitrary value of 1.0) (see values within the blots: nd not 
determined). ERK1/ERK2 were measured together, while GSK‑3α and 
GSK‑3β were separately analyzed. The blots are representative of 
one of at least three independent determinations, with qualitatively 
similar results. For other conditions see legend of Fig. 1
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stimulated p38-MAPK phosphorylation/activation, while 
the effect of 2-DG alone was negligible.
Once we examined protein kinase modulation, the 
potential importance of these alterations was investi-
gated using appropriate pharmacological inhibitors (the 
selected concentrations being adopted from our pre-
ceding studies with AML cells [44]). The results were as 
follows: (i) Co-treatment with the PI3K/Akt phospho-
rylation/activation inhibitors LY294002 (30 μM) or tricir-
ibine (10  μM) increased the apoptotic efficacy of 2-DG 
alone, and also augmented the slight apoptosis obtained 
with the combination of low concentrations of Quer 
(10  μM) plus 2-DG (2  mM) (Fig.  7a). This corroborates 
the role of Akt as a defensive kinase, and indicates that 
its inhibition by Quer may be at least in part responsi-
ble for the increased apoptosis in the combined (Quer/2-
DG) treatment. (ii) Co-treatment with the MEK/ERK 
inhibitors PD98059 (20 μM) or U0126 (5 μM) increased 
the apoptotic efficacy of Quer and 2-DG alone, and also 
augmented apoptosis by the Quer/2-DG combination 
(Fig. 7b). This indicates that ERK functions as a defensive 
kinase serving to restrain lethality by Quer and 2-DG, 
but may not account for the increased apoptotic effi-
cacy in the combined treatment. (iii) Co-treatment with 
the GSK-3 phosphorylation inhibitor SB216763 (10 μM) 
augmented the lethality of Quer and 2-DG alone and 
(although with lower efficacy) of the Quer plus 2-DG 
combination (Fig.  7c), indicating that drug-provoked 
GSK-3 phosphorylation/inactivation plays a defensive 
role. (iv) Finally, activation of p38-MAPK by Quer alone 
or Quer plus 2-DG seemed irrelevant for apoptosis, 
since the lethality was not modified by the pharmaco-
logic inhibitors SB203580 (10 μM) (Fig. 7d) or BIRB 796 
(0.1 μM: data not shown).
In final set of experiments, we analyzed Akt and 
ERK phosphorylation using other phenolic agents and 
Fig. 7 Effect of protein kinase inhibitors. The figure shows the capacity of protein kinase inhibitors to modulate apoptosis generation in HL60 cells 
by treatment with the indicated concentrations of Quer (μM) and 2‑DG (mM), alone or the combination. As a rule, the kinase inhibitors were applied 
1 h before the other drugs. a Effects of the PI3 K inhibitor LY294002 (LY, 30 μM) and the Akt inhibitor triciribine (Tric, 10 μM). b Effects of the MEK/ERK 
inhibitors U0126 (U, 5 μM) and PD98059 (PD, 20 μM). c Effects of the GSK‑3 inhibitor SB216763 (SB21, 10 μM). d Effects of the p38‑MAPK inhibitor 
SB203580 (SB20, 10 μM). Results are the mean ± S.D. of at least four determinations. Other conditions, including pre‑incubation with Quer in the 
combined treatments and symbols used in statistical analysis, were as in Fig. 1
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glycolytic inhibitors, as previously assayed for apoptosis 
(see Figs. 2 and 3). The results are represented in Fig. 8a–
c, and may be summarized as follows: (i) Gen (50  μM) 
produced qualitatively similar effects as Quer, namely 
rapid abrogation of 2-DG-provoked Akt phosphorylation, 
and (albeit with lower intensity) stimulation ERK activa-
tion when used alone. By contrast Cur (8 μM) was ineffec-
tive at 2 h, and required longer pre-treatment to suppress 
Akt activation. Moreover, under these conditions Cur, 
which did not per se affect ERK phosphorylation, pre-
vented the activation of this kinase by 2-DG (Fig.  8a). 
(ii) Lon was assayed at 6 and 14  h, since we previously 
showed that kinase activations by this agent are delayed 
in relation to 2-DG [11]. It could be observed that Quer 
abrogated or greatly reduced Lon-provoked Akt activa-
tion at both time periods (Fig.  8b). (iii) Finally, by con-
trast to the strong stimulatory effect of 2-DG, the basal 
Akt phosphorylation was not affected by glucose starva-
tion (Glu−), and co-incubation with Quer either did not 
affect (6 h) or caused a slight late decrease (20 h) (Fig. 8c). 
This correlates with apparent lack of lethality of glucose-
starvation, and the low apoptotic efficacy of Quer under 
these conditions (Glu−/Quer) in comparison to 2-DG/
Quer (see Fig. 3f ). By contrast, ERK phosphorylation was 
strongly stimulated by the combined (Glu−/Quer) treat-
ment (Fig. 8c).
Discussion
The present results indicate that that pre-treatment with 
low lethal concentrations of the flavonoid Quer strongly 
potentiates the anti-proliferative and apoptotic action 
of the glycolytic inhibitor 2-DG in HL60 AML cells. 
Apoptosis was assessed using different markers, namely 
DNA loss, phosphatidyl serine translocation, and ΔΨm 
Fig. 8 Effects of other polyphenols, lonidamine and glucose starvation on protein kinase activities. In (a) HL60 cells were incubated for 1 h with 5 mM 
2‑DG alone, or incubated for 2 or 14 h with 50 μM Gen or 8 μM Cur and then for 1 h more with or without addition of 2‑DG. In (b) HL60 cells were 
incubated for 6 or 14 h with 100 μM Lon, or incubated for 2 h with Quer and then for 6 or 14 h more with or without addition of Lon. The temporal 
sequence is indicated as (x–y h) at the top of the panels. In (c) HL60 cells were maintained in complete (glucose‑containing) medium (Cont), or incu‑
bated for the indicated time periods in glucose‑lacking medium (Glu−), with or without Quer. For other conditions see legends of Figs. 1 and 6
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decrease, and the protective action of z-VAD-fmk proves 
that it is in fact a caspase-mediated response. Our prec-
edent studies demonstrated that Quer and 2-DG, as well 
as the other agents used here (Lon, Cur and Gen) acti-
vated apoptosis throughout the mitochondrial (“intrin-
sic”) executioner pathway [11, 12, 20, 21, 29]. In this 
study we show that 2-DG and Quer, both of them char-
acterized as mitochondria-targeting drugs [7, 33], cause 
the rapid induction of mIMP (4 h), which may therefore 
represent a trigger or at least a necessary condition for 
apoptosis. Unfortunately the cause-effect relationship 
between mIMP and apoptosis could not be corroborated, 
due to the elevated toxicity of commonly used permeabil-
ity transition pore modulators (cyclosporine A, bongkre-
kic acid) in leukemia cell models ([45], and our data not 
shown).
Additional experiments corroborated the cooperative 
effect using other polyphenols (Cur, Gen), anti-glycolytic 
agents (Lon), and leukemia cell models (NB4 promye-
locytic, THP-1 promonocytic), although with different 
efficacy. For instance, Gen was less efficacious than Quer 
and Cur, and a moderately lethal concentration of the 
isoflavone was required to obtain good cooperation with 
2-DG. As possible explanations, Gen causes cell arrest at 
G2/M (see Additional file 3: Fig. S3) and also stimulates 
myeloid cell differentiation [22], which might temporar-
ily restrain the trigger of the apoptotic response. In the 
same manner, the efficacy of cooperation between Quer 
and 2-DG was lower in NB4 and THP1 than in HL60 
cells. This might be explained by intrinsic differences in 
molecular and biochemical properties and in the matu-
ration stage of these cell lines. For instance, in addition 
to the above indicated different susceptibility to 2-DG, 
THP-1 promonocytic cells are more resistant to Quer 
[46] (an in our experience also to other cytotoxic agents) 
than the less mature HL60 and NB4 cells. On the other 
hand, the finding that Quer plus 2-DG and Quer plus Lon 
induced apoptosis with similar efficacy allows to exclude 
that apoptosis potentiation may be a trivial consequence 
of polyphenol-provoked inhibition of GLUT 1 activity 
and 2-DG uptake, and hence of subsequent biochemical 
responses (e.g., 2-DG-provoked activation of defensive 
kinases, as discussed later). By contrast, the apoptotic 
efficacy of Quer was only marginally increased when 
2-DG treatment was substituted by glucose starvation. 
This indicates that the partial ATP depletion provoked 
by both treatments may affect cell proliferation, but it 
is not a determinant of drug lethality. Finally, a caution-
ary note must be expressed. We centered the attention 
on the apoptotic response, and for convenience (better 
observation of drug cooperation) selected sub-lethal drug 
concentrations. Nonetheless these concentrations caused 
appreciable anti-proliferative effects, as measured by the 
MTT assay (Fig. 1a) or by cell counting (the proliferation 
inhibition rates at 24 h, in relation to the control, were: 
43 % for 5 mM 2-DG; 5 % by 100 μM Lon; 44 % by 20 μM 
Quer; 21 % by 8 μM Cur; and 65 % by 50 μM Gen). This 
may be explained in some cases by cell cycle disruption 
(e.g., almost total G2/M arrest by Gen, and with lower 
intensity by Quer: see Additional file  3: Fig. S3). The 
molecular mechanisms responsible for Gen-provoked 
cycle arrest were investigated in a preceding article [22]. 
In addition, a possible activation of autophagy, which 
opposes apoptosis, may not be discarded.
The generation of apoptosis and/or necrosis by anti-
tumour drugs is frequently associated to oxidative stress, 
two manifestations of which are the increase in intra-
cellular ROS accumulation and the decrease in anti-
oxidant molecules such as GSH. For instance, we earlier 
demonstrated that the potentiation of arsenic trioxide 
(Trisenox)-provoked apoptosis by Lon and Gen was 
mediated by the stimulation of ROS production [11, 29], 
probably due to the interference of Lon and Gen with the 
mitochondrial respiratory chain [47, 48]. On the other 
hand, 2-DG was reported to decrease ROS [49, 50], while 
Quer may exert either inhibitory [33] stimulatory [37, 38] 
effects. Our present results confirm the drug-depend-
ent variability, and above all prove that the increase in 
lethality in the combined treatments (Quer plus 2-DG 
and Quer plus Lon) may not be adequately explained by 
ROS over-production. Thus, Quer not only reduced the 
basal ROS content, but exacerbated the decrease caused 
by 2-DG, and reversed the increase caused by Lon to 
levels lower than in untreated cells. In another study we 
observed that prolonged (14–24 h) treatment with Quer 
decreased the intracellular GSH content, and as a con-
sequence potentiated the lethality of the GSH-sensitive 
drug arsenic trioxide [20]. However a regulatory role of 
GSH may be excluded in the present conditions. In fact, 
Quer did not cause early changes in GSH content, and 
the impact on apoptosis of a potential long-term altera-
tion may be discarded, in view of the lack of effects of 
GSH specific inhibitor BSO.
Finally, the present results corroborate the capac-
ity of 2-DG and Lon to stimulate Akt activation in AML 
cells, and demonstrate that the stimulation is abrogated 
or attenuated by co-treatment with Quer, Gen and Cur, 
which at the same time potentiate apoptosis. The cause-
effect relationship between Akt inhibition and apoptosis 
potentiation was supported by experiments using stand-
ard pharmacologic protein kinase inhibitors, and was also 
strengthened by the results obtained using glucose-free 
medium, where the lack of Akt activation correlates with 
poor Quer lethality. There are nevertheless some quanti-
tative differences: thus, Akt activation by Lon was delayed 
in relation to 2-DG; a prolonged pre-treatment with Cur 
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(14 h) was required to abrogate 2-DG-provoked Akt acti-
vation; and 50 μM Gen sufficed to block 2-DG-provoked 
Akt activation, although the pro-apoptotic action of this 
Gen concentration was poor. The discrepancies might be 
explained by the particular action mechanisms of the used 
drugs, and also indicate that Akt inhibition is an impor-
tant factor but not the only one accounting for apoptotic 
potentiation in the combined treatments. Noteworthy, 
prolonged pre-treatment with Cur also abrogated 2-DG-
provoked ERK activation, indicating that at least in some 
circumstances this kinase also regulates apoptosis poten-
tiation in the combined treatments. Nonetheless the 
function of ERKs in the present experiments is less clear, 
mainly because the disparity of effects caused by poly-
phenols. Thus, ERK phosphorylation was strongly stimu-
lated by Quer, slightly stimulated by Gen, and unaffected 
by Cur. Of note, co-treatment with MEK/ERK inhibitors 
increased the apoptotic efficacy of Quer alone. It seems 
therefore that ERK activation serves to restrain excessive 
polyphenol toxicity, in the same manner as 2-DG toxicity. 
In addition Quer, alone or with 2-DG, caused p38-MAP 
activation, but this response seems irrelevant for apopto-
sis as judged by the null effect of kinase inhibitors. This 
conclusion is consistent with results obtained by other 
authors using a Quer analogue [43]. Finally, earlier reports 
indicated that 2-DG elicits Akt-dependent GSK-3β phos-
phorylation [13] while quercetin increases [51] or does not 
affect [52] kinase phosphorylation. Using pharmacologic 
inhibitors, other articles proved that GSK-3 regulates cell 
growth and/or apoptosis in leukemia cells [53–55]. Our 
present results indicate that Quer and 2-DG cause hyper-
phosphorylation (Ser21/9)/inactivation of GSK-3α/β in 
HL60 cells, although with certain drug-specificity. Thus, 
Quer (which only activated ERKs) preferentially stimu-
lated the α isoform, while 2-DG (which activated Akt and 
ERKs) stimulated both α and β isoforms. Most studies in 
the literature only centered the attention on GSK-3β, but 
some reports call attention on the functional importance 
of the α isoform. As an example, GSK-3α knock-down 
reduced proliferation and caused spontaneous apoptosis 
[56], and potentiated bortezomib-induced toxicity [57], 
in leukemia cells. Our results show that the GSK-3 inhibi-
tor SB216763 (10  μM) does no cause per se significant 
lethality, but potentiates apoptosis induction by Quer and 
2-DG, alone and in combination, in HL60 cells. Since as 
commented above Quer preferentially stimulates GSK-3α, 
we might postulate that this isoform is the most impor-
tant for regulation of Quer lethality. Unfortunately the 
lack of specificity of the up to date available pharmaco-
logic inhibitors, and the difficulty to perform satisfactory 
knock-down procedures in the used leukemia cell model, 
impeded us until now to obtain more clear conclusions.
Conclusions
De-regulation of the MEK/ERK and especially the PI3K/
Akt pathway are among the most frequent alterations 
associated to the generation of the tumour phenotype, as 
well as to the intrinsic or acquired resistance of tumour 
cells to anti-cancer treatments. Dietary phenolic agents are 
in general well tolerated, and might therefore be preferable 
to approach the problem instead of synthetic pharmaco-
logic drugs. The present results indicate that co-treatment 
with low concentrations of selected polyphenols increase 
the apoptotic efficacy of the glycolytic inhibitors 2-DG 
and Lon in human acute AML cell models, and that this 
effect may be at least in part explained by the prevention 
of defensive protein kinase activation, mainly Akt and in 
some circumstances ERKs. Of course, we did not attempt 
performing an exhaustive study: in fact, polyphenols affect 
multiple biochemical and molecular mechanisms other 
than Akt inhibition [16–18], 2-DG is a dual glycolysis and 
N-glycosylation inhibitor [4], and Lon inhibits glycolysis 
but also lactate transport (causing intracellular acidifica-
tion) and mitochondrial respiration [5, 48]. In spite of the 
conceptual and technical limitations we believe that our 
in vitro study may offer some ideas to improve the efficacy 
of this potentially important group of anti-tumour drugs.
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